Free

Midwest CEPAC Meeting: Voretigene Neparvovec

Event Information

Share this event

Date and Time

Location

Location

Courtyard by Marriott Kansas City

4000 North Mulberry Drive

Kansas City, MO 64116

View Map

Friends Who Are Going
Event description

Description

The Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), a core program of the Institute for Clinical and Economic Review (ICER), is a nationally-recognized community forum. The Midwest CEPAC convenes three times each year at public meetings to review objective evidence reports and develop recommendations for how stakeholders can apply evidence to improve the quality and value of health care. Midwest CEPAC directly engages clinicians, patients, and payers during public meetings to discuss implications of the evidence for clinical decision-making and coverage policies. Application of evidence takes shape through new medical policies, benefit designs, and patient and clinician tools to improve clinical care and patient outcomes.

On January 25, 2018, the Council will review the ICER Evidence Report on Voretigene Neparvovec for Biallelic RPE65-Mediated Retinal Disease. Inherited retinal diseases (IRDs) are an important cause of childhood blindness. Effective treatments to reverse or slow IRDs have been generally unavailable. Voretigene Neparvovec is an investigational gene therapy for RPE65- Mediated IRDs. If approved, Voretigene Neparvovec would be the first gene therapy apprived in the US.

The meeting will be held in the Views I, II, III at Visions KC at the Courtyard Kansas City at Briarcliff Marriott. For more information, and to view reports and meeting materials as they become available, please visit the ICER website.

Share with friends

Date and Time

Location

Courtyard by Marriott Kansas City

4000 North Mulberry Drive

Kansas City, MO 64116

View Map

Save This Event

Event Saved